Triple-combination rilpivirine, emtricitabine, and tenofovir (Complera™/Eviplera™) in the treatment of HIV infection

Overview of attention for article published in Patient preference and adherence, June 2013

Altmetric Badge

Mentioned by

twitter: 2 tweeters

facebook: 1 Facebook page

Citations

dimensions_citation: 14 Dimensions

Readers on

mendeley: 43 Mendeley

Summary Twitter Facebook Dimensions citations

So far, Dimensions has found 14 publications that cite this research output.

14

The most recent citing publications are shown below. View all 14 publications that cite this research output on Dimensions.

DEVELOPMENT, VALIDATION OF RP-HPLC METHOD FOR THE SIMULTANEOUS ESTIMATION OF TENOFOVIR DISPROXIL FUMARATE, EMTRICITABINE AND RILPIVIRINE HYDROCHLORIDE IN BULK, FORMULATION AND USED IN NANOSUSPENSION

Article in INDIAN DRUGS (September 2019)

Rilpivirine as a potential candidate for the treatment of HIV-associated neurocognitive disorders (HAND)

Article in Journal of Molecular Histology (April 2019)

Accumulated pre-switch resistance to more recently introduced one-pill-once-a-day antiretroviral regimens impacts HIV-1 virologic outcome

Article in Journal of Clinical Virology (May 2018)